跳转至内容
Merck
CN
所有图片(2)

文件

ABC490

Sigma-Aldrich

Anti-BCL2A1/BFL-1 Antibody

from rabbit, purified by affinity chromatography

登录查看公司和协议定价

别名:
BCL2A1/BFL-1, Bcl-2-related protein A1, Bcl-2-like protein 5, Bcl2-L-5, Hemopoietic-specific early response protein, Protein BFL-1, Protein GRS
UNSPSC代码:
12352203
eCl@ss:
32160702
NACRES:
NA.41

生物来源

rabbit

质量水平

抗体形式

affinity isolated antibody

抗体产品类型

primary antibodies

克隆

polyclonal

纯化方式

affinity chromatography

种属反应性

human

种属反应性(根据同源性预测)

bat (based on 100% sequence homology), chimpanzee (based on 100% sequence homology), bovine (based on 100% sequence homology), Camelidae (based on 100% sequence homology)

技术

immunohistochemistry: suitable
western blot: suitable

NCBI登记号

UniProt登记号

运输

wet ice

靶向翻译后修饰

unmodified

基因信息

human ... BCL2A1(597)

一般描述

Bcl-2-related protein A1 (BCL2A1), also known as protein BFL-1, protein GRS, and Bcl-2-like protein 5 (Bcl2-L-5), is a member of the Bcl-2 family. BCL2A1/BFL-1 can interact with Bax and suppress apoptosis by inhibiting the release of cytochrome c and caspase-3 activation. BCL2A1/BFL-1 expression is reported in peripheral blood, spleen, bone marrow, lung, small intestine, and testis.

免疫原

KLH-conjugated linear peptide corresponding to the near N-terminal of human BCL2A1/BFL-1.

应用

Anti-BCL2A1/BFL-1 Antibody is an antibody against BCL2A1/BFL-1 for use in Western Blotting and Immunohistochemistry.
Immunohistochemistry Analysis: A 1:50-250 dilution from a representative lot detected BCL2A1/BFL-1 in human breast cancer and human bone marrow tissue.

质量

Evaluated by Western Blotting in human spleen tissue lysate.

Western Blotting Analysis: 1.0 µg/mL of this antibody detected BCL2A1/BFL-1 in 10 µg of human spleen tissue lysate.

目标描述

~18 kDa observed

其他说明

Concentration: Please refer to lot specific datasheet.

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Warren Fiskus et al.
Blood cancer journal, 12(1), 5-5 (2022-01-13)
Treatment with Menin inhibitor (MI) disrupts the interaction between Menin and MLL1 or MLL1-fusion protein (FP), inhibits HOXA9/MEIS1, induces differentiation and loss of survival of AML harboring MLL1 re-arrangement (r) and FP, or expressing mutant (mt)-NPM1. Following MI treatment, although

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门